Genesis Diagnostics
Novacyt, Genesis Diagnostics Ink Supply Deal
As part of the deal, which is worth at least $3 million for the first five years, Primerdesign will develop and supply 384-well plate molecular assay panels for Genesis.
AmberGen is developing a microbead-based, multiplexed, in vitro pediatric allergy test. The diagnostic is designed to enable the detection of multiple allergen-specific IgE antibodies in blood, according to a company executive.
The British company expects to report "substantial growth" in its food intolerance testing line for full-year 2009, and sales of its microarray-based Genarrayt platform are expected to rise 44 percent to £1.04 million from £72,000 in 2008.
The service is SRL's first array-based test and could foreshadow the adoption of more array-based diagnostics by the Indian testing giant.